Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.

Angiology (Impact Factor: 2.37). 09/2001; 52 Suppl 1:S49-56. DOI: 10.1177/000331970105200107
Source: PubMed

ABSTRACT Chronic venous insufficiency (CVI) affects a large number of people in Western countries, and is responsible for considerable inconvenience, discomfort, suffering, and costs. Micronized purified flavonoid fraction (MPFF, 450 mg diosmin plus 50 mg hesperidin-Daflon 500 mg) is a potent venotropic drug used in the treatment of venous insufficiency. Pharmacological and clinical studies demonstrated the comprehensive mode of action of Daflon 500 mg: it increases venous tone, it improves lymph drainage, and it protects the microcirculation. Clinical international, prospective, multicenter, randomized, controlled studies versus placebo studies documenting the effects of Daflon 500 mg in CVI at advanced stages with edema, skin changes, and venous leg ulcer are reviewed. In edema, one of the most frequent complaints of patients, Daflon 500 mg brings about a significant reduction in leg circumference, thanks to its capacity to inhibit inflammatory reactions and to decrease capillary hyperpermeability. The rationale for the use of Daflon 500 mg for treatment of skin disorders and venous leg ulcer is its action on the microcirculation-damaging processes. Regarding skin changes, Daflon 500 mg has been shown to improve venous trophic disorders, like gravitational (stasis) dermatitis, and dermatofibrosclerosis. In venous leg ulcer, Daflon 500 mg's clinical efficacy has been demonstrated in addition to standard treatment or versus standard treatment alone. Daflon 500 mg, thanks to its comprehensive mode of action on the veins, lymphatics, and microcirculation, is the method of choice not only in the early stages of CVI treatment, but also in the severe stages of this condition, in combination with compression treatment, sclerotherapy, and surgery if appropriate.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Six related substances were detected in diosmin bulk drug substances and products by a newly developed gradient reverse-phase high performance liquid chromatography (RP-HPLC) with UV detection. The chromatographic system consisted of an Intersil Wondasil TM ODS (C 18) column (250 × 4.6 mm; 5 μm). The mobile phase consisted of water/acetic acid 66:6 v/v (solvent A) and methanol (solvent B) using a gradient program at a flow rate of 0.8 mL min−1 with 345 nm detection and an injection volume of 20 μL. In addition, the linearity, quantitation limit (QL), accuracy, selectivity, robustness and precision were determined. Good linearity was obtained over the concentration range 0.5–200 μg mL−1 with the coefficient of determination (r 2) of 0.999. The QL was 0.125 μg mL−1 (relative standard deviation <2.0 %). The major impurities have been resolved and identified using two analytical systems, HPLC and HPLC/electrospray ionization-mass spectrometry operated in a negative ion mode. One of these impurities marked as 7-hexopyranosidal diosmetin was unknown and has not been reported previously. Based on mass spectrometry data the structure of the new impurity was proposed as 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-4H-chromen-7-yl hexopyranoside. The newly developed RP–LC method for quantitative determination of diosmin-related substances was found to be precise, accurate, robust and specific. It has been successfully employed for the quality evaluation of different sources of raw material and generic formulations of diosmin.
    Chromatographia 76(9-10). · 1.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pathophysiological events involved in the onset of chronic venous ulceration (CVU) are inflammation, activation of polymorphonucleates (PMNs) and secretion of proteases such as matrix metalloproteinases (MMPs), which degrade extracellular matrix (ECM) that is a support for vascular and tissutal wall. MMPs, neutrophil gelatinase-associated lipocalin (NGAL) and inflammatory cytokines are overexpressed in CVUs and they could play a central role in pathophysiological mechanisms of skin lesion and delayed wound healing. Bioflavonoids, such as diosmin and other compounds, appear to have several provessel function activities including anti-inflammatory, antioxidant and phlebotonic effects and are widely used in the treatment of chronic venous disease (CVD)-related problems. In this article, we evaluated the effects of Axaven®, a new nutraceutical on both clinical and molecular parameters in patients with CVUs. During the study period, 36 patients with CVUs of both sexes were enrolled and divided into two groups: group A (treated group): nine females and seven males (median age is 67·7 years) received standard treatment (compression therapy and surgical correction of superficial venous incompetence) + Axaven® once a day for 8 months as adjunctive treatment. Group B (control group): 11 females and 9 males (median age is65·5 years) were treated only with basic treatment according to their clinical conditions. In our study, the administration of Axaven® in patients with CVUs was able to decrease inflammatory cytokines, MMPs and NGAL, inducing an improvement of both symptoms with an increase of the speed of wound healing.
    International Wound Journal 02/2014; · 1.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Melanoma metastasizes in approximately one third of patients, causing a drop in survival of 1-2% at two years. The only effective treatment is Interferon alpha (IFN α) at elevated doses, which is highly toxic. Thus, less toxic antitumoral agents are being sought, among which flavonoids are to be highlighted. Our aim was to study the combined treatment of metastasic lung melanoma with IFN α and diosmin in a murine model. Material & Methods 60 Swiss mice inoculated with cells (5 × 105) from the B16F10 murine melanoma cell line, treated over 11 days prior and 21 days following inoculation: Group I: ethanol + PBS; Group II: ethanol + IFN α (600,000 IU); Group III: ethanol + IFN α (1,200,000 IU); Group IV: diosmin + PBS; Group V: diosmin + IFN α (600,000 IU); Group VI: diosmin + IFN α (1,200,000 IU). Following treatment, animals were sacrificed and a macroscopic count of subpleural metastasic nodules was performed. Results We found significant differences between the control and the treated groups (p<0.001), there being a greater drop in the number of subpleural metastasis in group III with respect to the control (79.74%; p<0.001), followed by group V (77.38%; p<0.001), VI (72.33%; p<0.001), IV (61.4%; p<0.001) and II (59.59%; p<0.001). Conclusions The combination of diosmin with the lower dose of IFN α showed a strengthening of the anti-metastasic action of both compounds, being equally as effective as the highest dose of IFN α on its own.
    Revista Española de Patología. 01/2008; 41(2).